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provide patient files (1) containing relevant microbiological and non- 
microbiological (e.g. date of admission, time of surgery) information, 
thus requiring LIS/HIS connection, and (2) organized in a compre- 
hensive and workable manner (i.e. ready to use ‘at a glance’); the LIS 
should be able to generate qualitative/quantitative indicators for alert 
(e.g. readmission of an MDR carrier) and survey (e.g. list of patients 
with probable nosocomial infection), as well as workflows for inter- 
vention; a capability and willingness to communicate and interact 
should be encouraged by the institution through technician/MD 
training in basic epidemiology and case presentations in order to 
promote flexibility and responsiveness as an integral attribute of 
medical microbiology. 
Active involvement 
M. Tvede. Rigshospitalet, Copenhagen, Denmark 
Multiresistant bacteria are rarely seen in Danish hospitalized patients. 
Among other examples, MRSA occurred in only 0.5% in all tested 
strains in 1997, and vancomycin-resistant Enterococcns fecalis has only 
been described in two patients over the last 5 years. Additionally, 
aminoglycoside and quinolone resistances in E .  coli remain under 1% 
of the tested strains, with the penicillin resistance rate in pneumo- 
cocci only about 0.7%. These results should be considered in 
conjunction with the world’s lowest total usage of antibiotics, and 
with a low and controlled use of broad-spectrum antibiotics. These 
facts led us to identify the main reasons in our clinical microbiology 
daily practice and general organization which can explain this 
enjoyable situation. Improved intervention capabilities and effective 
communication with the different healthcare partners in the hospital 
enable the microbiologist to routinely act as a consultant and to 
actively contribute to critical healthcare management decisions. As a 
result, early diagnosis with appropriate antibiotic prescription is part 
of the normal routine in infectious diseases. Further efticiency is 
derived from successful development and implementation of 
antibiotic policy and laboratory networking. We would like to share 
our working experience and successes and propose useful recom- 
mendations which could reduce the spread of antibiotic resistance 
and prevent its predictable, negative consequences. 
The positive impact of clinical microbiology 
M.R. Gismondo. L. Sacco Teaching Hospital, Milan, Italy 
In the last 30 years we have seen great developments in the micro- 
biology laboratory, in both bacteriology and virology Bacterial 
isolation and identification and the related antibiotic susceptibility 
tests have become routine when the symptoms indicate the necessity. 
Thus, it is now possible to control the evolution ofinfectious diseases, 
the frequency of microbial isolation in various infections and anti- 
microbial resistance. However, today the healthcare system faces a 
rather peculiar situation with careful spending habits and an increas- 
ing unwillingness on the part of hospitals to invest in elements that 
cannot demonstrate immediate positive impact on patient care. 
Furthermore, the turnaround time for bacteriologic results does not 
always coincide with the amount of time needed to perform the test. 
This makes the optimization of not only pre-analytic and analytic 
stages of the test indispensable, but also the post-analytic stage. In 
parallel, it is very critical to demonstrate the usefulness of clinical 
microbiology in terms of both medical value for the patient and 
healthcare economic advantages. This can be achieved by compiling 
a clear and efficient report and by creating a close working relation- 
ship with the physicians. Formal and informal channels must be used 
to capture the attention of physicians, to demonstrate the correct use 
of antibiotics and to cooperate in preventing and limiting the spread 
of nosocomial infections. Formal cooperation ofmicrobiologists with 
hospital committees must complement this approach. The author 
will propose suggestions in order to obtain complete professional 
recognition ofthe clinical microbiologist from physicians, and to gain 
recognition of the economic advantages to be obtained in patient 
healthcare. 
Quality aspects in clinical microbiology 
wl Reporting strategies in clinical microbiology 
C. Block. Hadassah University Hospital, Clinical Microbiology and 
Infectious Diseases, ]emsalem, Israel 
The presentation of laboratory results to physicians has been the 
concern of laboratory directors since laboratories began. Clinical 
microbiology is a discipline so complex and constrained by techno- 
logical growth retardation that special demands and responsibilities 
are placed on laboratory directors to ensure accurate, relevant and 
dependable reporting. Providing detailed, comprehensive misleading 
reports is a frequent pitfall facing clinical microbiologists. Some 
investigators have proposed minimizing these flaws by utilizing 
strategies that impinge on the entire laboratory process, from receipt 
of specimens to design and delivery of reports. Simply put, a 
reporting strategy is a form of presenting laboratory test results 
designed to achieve a desired effect, e.g. to influence clinical practice. 
Strategies have been used for promoting prudent antibiotic use and 
have deployed integrative computer functions combining suscepti- 
bilities with biochemical, hematologic and radiologic data to assist 
infectious disease consultants or clinical pharmacists and alert them 
to problems. Reporting on underfilling of blood cultures is being 
evaluated as a measure for improving practice. Education of clinicians 
might include detailing rejection criteria for unacceptable specimens, 
communicating taxonomic changes, and adding reminders regarding 
notifiable dlseases and isolation alerts. Integral to a l l  the above is the 
obligation to ensure that the system works as it should. In some coun- 
tries regulation has forced the application of (sometimes extreme) 
quality assurance and validation procedures. Elsewhere, only the 
regulator’s compulsion is lacking. The professional and ethical obliga- 
tions of laboratory directors to ensure that the system delivers the 
goods are the same. 
Internal and external quality control for virus 
genome detection 
H. Zeichhardt’, H.-€? Grunert’, K.-0. Habermehl’. ‘Department of 
Virology, Institutefor Infections Diseases Medicine, University Hospital 
Benjamin Franklin, Free University of Berlin, Zlnstitutefor 
Biotechnological Diagnosticr, Berlin, Germany 
Objectives: Internal and external quality control have been directly 
interconnected in Germany since 1997 for improving and standard- 
izing the performance of virus genome detection by polymerase 
chain reaction and other nucleic acid amplification techniques. 
Methods: External quality assessment schemes (EQASs) for 
qualitative and quantitative genome detection of human immuno- 
deficiency virus 1 (HIV-l), hepatitis C virus (HCV) and hepatitis B 
virus (HBV) as well as qualitative detection of herpes viruses 
(cytomegalovirus, varizella zoster, and herpes simplex viruses types 1 
and 2) are performed twice a year by up to 180 laboratories. These 
EQASs are organized by the ’Institute for Standardization and 
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Documentation in the Medical Laboratory' (INSTAND) and under 
the auspices of three scientific societies (DVV, GN, DGHM). 
Lyophilized plasmas positive for HIV-1, HCV or HBV, or lyophilized 
debris of cells infected with one of the herpes viruses, are prepared 
in large quantities for external and internal quality controls. 
Results and conclusions: Shortly after a given EQAS, these 
EQAS camples are available for daily internal quality control of 
routine diagnostics as well as evaluation and standardization of new 
tests by laboratories, companies, and authorities (e.g. Paul Ehrlich 
Institute). O n  the basis of these materials, national working references 
were prepared for qualitative and quantitative detection of HCV 
(genotype lb;  30 000 and 3000 geq/mL) and HIV-1 (subtype B; 
40 000 and 4000 geq/mL). The regular participation at the EQASs 
and the use of EQAS samples and national working references have 
been proven to raise the rate of correct quantitative HIV-1 detection 
from 85% to 98%. 
/s25] Outcome analysis 
A. von Graevenitz. Department vf Medical Microbiology, University o j  
Zurirb, Zurich, Switzerland 
Laboratory resources have been strained by costs of new tests, salaries 
of personnel, equipment, etc. More and more, a laboratory is 
required to justify certain expenses, and even its existence. A tool for 
the evaluation of a laboratory's purpose and performance is outcome 
analysis. Possible kinds of outcome refer to the laboratory itself (e.g. 
staffing, turnaround time of testing, cost of supplies and equipment), 
patient care (e.g. length of hospital stay, mortality, various costs) or  
the reputation of the laboratory (e.g. physician satisfaction). 
To assess the consequences and cost of changes, a program called 
BASICC (Basic Assessment Scheme for Intervention Costs and 
Consequences) may be used and has at its endpoint 'net cost', defined 
as cost of program plus cox of side effects minus cost of outcome 
averted (see M M W R  1995; 44/RR(10): 1-10). This formula pre- 
supposes knowledge of patient care costs per defined diagnosis, and 
of the cost and outcome without the planned changes. Outcome 
analysis may be applied to the use of certain tests (e.g. antigen testing, 
broth enrichments, smears), communication channels (e.g. order 
forms) or statistics. Examples will be provided. 
Intestinal protozoa and echinococcosis 
ms27) Cyclospora and microsporidia: clinical and 
diagnostic aspects 
R. Weber. Ittfirtiotrz Diseases, University Hospital, Zurich, Switzerland 
Cyclospora rayctanensis, previously termed blue-green alga, 
cyanobacteriuni-like body, or coccidia-like body, was recently 
characterized as belonging to the coccidians. It has been identified 
worldwide in stool speciniens of iinniunocompetent and iinmuno- 
coinproniised patients. The spectrum of illness is not yet fully defined 
but it may range from asymptomatic carriage of the organism to 
severe and prolonged diarrhea in immunocompetent and immuno- 
compromised patients. Prevalence data have yet to be assessed. The 
parasite is transmitted by the fecal-oral route and infection is most 
probably acquired from contaminated water or food. Diagnosis is 
dependent on light microscopic detection of the oocysts. Controlled 
trials showed that cotrimoxazole was clinically successful and 
shortened oocyst shedding. 
Microsporidia are obligate intracellular, spore-forming protozoa. 
Seven genera (Entcroryfozoon, Encephnbforoori, Nuscrira, Bracbiola, 
Krtaforma, Pleistophora, Trackiplrictophora) and unclassified niicro- 
sporidia can infect humans. The sources of niicrosporidia and modes 
of transmission are uncertain. Microsporidiosis occurs primarily in 
persons infected with HIV, but it is also emerging in otherwise 
immunocompromised hosts and in iminunocompetent individuals. 
The most robust technique for diagnosis of microsporidiosis is the 
light microscopic detection of the parasites. Species identification is 
made using electron microscopy, antigenic analy$is, or molecular 
analysis. The clinical manifestations include intestinal, ocular, nius- 
cular, cerebral, respiratory and urinary tract disease. Treatment with 
albeiidazole can result in cure of encephalitozoonosis. No therapy is 
available for enterocytozoon infection. An improvement of immune 
function following highly active antiretroviral treatment may lead to 
parasite clearance in infected persons with AIDS. 
I S28 I Host tissue destruction by Entamoeba 
histolytica 
E. Tannich. Bemhard Nocbt Inst., Molerrilar Parasitolqy, Hatnburg, 
Gevmariy 
The protozoan parasite Entamoeba histolytica is characterized by its 
extraordinary capacity to destroy human tissues, leading to massive 
and sometimes lethal pathologic alterations such as ulcerative colitis 
or abscesses of various organs, most conimonly of the liver. Recent 
studies have indicated that at least three functions of the amoebae are 
important for pathogenic tissue invasion. Pathogenicity ic viewed as 
the result mainly of (1) adherence of the amoebae to host cells, 
predominantly mediated by a galactose- and N-acetylgalactosaniine- 
inhibitable surface lectin, (2) killing of host cells by pore-forming 
peptides known 3s amoebapores, and (3) proteolysis of the host's 
extracellular matrix mediated by cycteine proteinases. Structural 
detailed molecular analysis including cloning of the corresponding 
genes from E. histolytica and from the non-pathogenic species E.  
dispar have led to a better understanding of the function of these 
proteins. 
Immune responses in alveolar echinococcosis 
B. Gottstein. Iirstiti~te (f Parasitology, Utiiuersity of Brrnc, Berne, 
Switzerland 
Infection with E.  ntuftilocularis encounters either constitutional resist- 
ance, late resistance or full susceptibility to alveolar echinococcosis 
(AE). Dissection of humoral, cell-mediated and cytokine-mediated 
immune responses in susceptible and resistant humans showed 
differences partially dependent on host M H C  class I1 polymorphism. 
Thus progressive AE was associated with D R 3  and DQ2, whereas 
D R l  1 was associated with improved AE prognosis. DR1 3 was m o s  
frequent in cured AE patients. A niuriiie AE model (C57BL/6) 
allowed uc to document a marked initnunosuppression phenomenon 
characterized by significantly suppressed splenocyte proliferative 
responses to ConA and to Emc antigen. Conversely, splenic cytokine 
production (IL-2, IL-4, and IFN-gamma) remained non-suppressed. 
Infection in mice resulted in strong Mac-1 cell infiltration of the 
peritoneal cavity and spleen. Corresponding PEC from infected mice 
expressed significantly higher levels of inflammatory cytokine 
transcripts for IL-1, TNF-alpha and iNOS than that from non- 
